Guardant Health, Inc. (NASDAQ:GH) Receives Average Recommendation of "Buy" from Analysts

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) has been assigned an average rating of "Buy" from the twenty-one research firms that are currently covering the company, Marketbeat Ratings reports. Twenty equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $49.00.

Several research firms have commented on GH. Raymond James restated an "outperform" rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Canaccord Genuity Group raised their target price on shares of Guardant Health from $42.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, February 24th. Mizuho assumed coverage on shares of Guardant Health in a report on Thursday, April 10th. They set an "outperform" rating and a $55.00 price objective on the stock. Stephens restated an "overweight" rating and set a $55.00 target price on shares of Guardant Health in a report on Wednesday, March 26th. Finally, Barclays decreased their price objective on Guardant Health from $60.00 to $55.00 and set an "overweight" rating for the company in a research note on Thursday, April 10th.

Institutional Investors Weigh In On Guardant Health

A number of hedge funds have recently modified their holdings of GH. NewEdge Advisors LLC boosted its stake in shares of Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company's stock valued at $59,000 after buying an additional 230 shares during the period. Summit Investment Advisors Inc. raised its position in shares of Guardant Health by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 12,346 shares of the company's stock worth $377,000 after acquiring an additional 391 shares in the last quarter. Arizona State Retirement System boosted its holdings in Guardant Health by 1.1% in the fourth quarter. Arizona State Retirement System now owns 35,639 shares of the company's stock valued at $1,089,000 after purchasing an additional 403 shares in the last quarter. Jones Financial Companies Lllp increased its stake in Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after purchasing an additional 817 shares during the last quarter. Finally, Fiduciary Alliance LLC raised its holdings in Guardant Health by 7.6% during the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock worth $363,000 after purchasing an additional 836 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Trading Up 3.3 %

Shares of NASDAQ:GH traded up $1.52 during trading on Friday, reaching $47.16. The company's stock had a trading volume of 290,720 shares, compared to its average volume of 2,134,487. The stock has a market capitalization of $5.82 billion, a PE ratio of -13.24 and a beta of 1.45. The firm's 50 day simple moving average is $43.39 and its two-hundred day simple moving average is $36.82. Guardant Health has a 12 month low of $16.77 and a 12 month high of $50.89.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). The firm had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Research analysts anticipate that Guardant Health will post -2.9 EPS for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.